While Abbvie and Express Scripts announced their deal on Viekira Pak, which was approved in late December to treat hepatitis C, CVS/Caremark today announced that several of it's plans would provide exclusive coverage to Gilead's Sovaldi/Harvoni.
Gilead Sciences' (GILD) hepatitis C drugs, Sovaldi and Harvoni, will get exclusive coverage on several plans from CVS/Caremark (CVS), the pharmacy benefits manager said Monday, taking the opposite stance from competitor Express Scripts.
Gilead shares spiked on the news Monday, driving up the entire biotech sector. Last month, shares of Gilead swooned after Express Scripts (ESRX) said it would exclusively offer competitor AbbVie's (ABBV) newly approved hepatitis C therapy on its largest plan.
"CVS/Caremark has completed a thorough evaluation of the existing and new hepatitis C therapies that are now available in the marketplace," Chris Cramer, a spokeswoman for CVS Health, said in an email statement. The news was first reported by Dow Jones. "As a result of that evaluation, effective January 7, 2015, Harvoni and Sovaldi-manufactured by Gilead Sciences Inc.-will be exclusive on the CVS/Caremark Standard Commercial, Exchange (Marketplace), Medicare Part D and Medicaid formularies. "
Read the complete article on Yahoo!: http://yhoo.it/1xLo4Y7
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Early Involvement Critical in Treating Immunotherapy-Induced Overlap Syndrome
April 19th 2024A series of case studies reveals the importance of early diagnosis and involvement of special teams of clinicians when dealing with potential cases of overlap syndrome, which encompasses myocarditis, myasthenia gravis, and immune checkpoint inhibitor–related myositis.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen